RALEIGH, N.C., June 10, 2015 (GLOBE NEWSWIRE) -- INC Research Holdings, Inc. (Nasdaq:INCR), a leading global Phase I to IV contract research organization, will demonstrate its focus on clinical innovation and continued commitment to clinical research sites with an extensive presence at the DIA 2015 51st Annual Meeting June 14-18 at the Walter E. Washington Convention Center in Washington, D.C. In addition to participating in eight educational sessions, INC Research executives will be on-hand at Booth #2303 to discuss the need for rapid innovation in clinical research, with a focus on further incorporating the site voice in clinical development and maximizing the potential that risk-based monitoring (RBM) strategies bring to new drug development.
"There is significant opportunity to inject innovation into many facets along the drug development continuum," said INC Research CEO Jamie Macdonald. "DIA brings together representatives from all parts of the clinical trial value chain to share key insights and put those that have the most potential to reduce complexity into effective clinical practice. At this year's meeting, INC Research is delighted to host its second annual Site Appreciation Reception at DIA to thank our clinical research site partners who are instrumental to the success of our studies and our ability to develop new medicines for the patients who need them."
Demonstrating the impact of RBM
INC Research will share its latest findings related to RBM at DIA in a new white paper titled "Embracing risk-based monitoring to drive clinical development forward" that outlines how meaningful efficiencies can be achieved through implementation of different clinical monitoring strategies. The data suggest that the potential to generate significant efficiency gains is based on the trial's risk profile, site data volume and the ability to implement centralized data review. Using the Company's unique approach to RBM called strategic data monitoring (SDM), which has been implemented in more than 25 trials and takes a holistic view of study monitoring, INC Research improved efficiency through reduced source data verification (SDV) monitoring and centralized monitoring. The white paper can be downloaded here and will be available at INC Research's booth.
Joining CISCRP in honoring clinical trial participants – Medical Heroes 5K Walk & Run
INC Research is an Elite Sponsor of CISCRP's 5K Walk & Run taking place Monday, June 15, at 6:30 a.m. to coincide with the DIA 2015 Annual Meeting. A team of INC employees will take part in this important event to celebrate the volunteers who participate in clinical research, with proceeds supporting education and outreach programs to patients and families. To register or donate, visit https://www.ciscrp.org/programs-events/events/medhero5k-DC/.
Recognizing the invaluable contributions of clinical research sites
As part of its ongoing commitment to recognize the importance of clinical research sites to the drug development process, INC Research is hosting its annual Site Appreciation Reception for site representatives on Tuesday, June 16, from 5:30 to 8:30 p.m. INC Research CEO Jamie Macdonald and Vice President of Site and Patient Access Clare Grace, along with SCRS President Christine Pierre, will meet with clinical research site professionals to discuss ways to improve future collaborations for the benefit of patients. For more information on this event, interested sites should visit booth #2303. To view a video from last year's DIA site event, click here.
Contributing to the discussion
At DIA, INC Research thought leaders will contribute to discussions on the following topics:
- Elaine Taylor, Senior Director, Regulatory Consulting
"Successful Drug Development: Best Practices for Clinical Trials Design, Agency Interactions and Regulatory Document Writing"
Pre-Show Tutorial, Sunday, June 14, 8:30 a.m.
- Andrew Townshend, Senior Vice President, Alliance Development
"Adventures in Strategic Planning: Is the FSP Model Dead?"
Forum, Monday, June 15, 8:30 - 9:30 a.m., Room 150A
- Neil Ferguson, Executive Vice President, Business Development
"What Contract Research Organizations Value in a Partner: Results of a Perception Survey"
Session, Monday, June 15, 11 a.m. - 12 p.m., Room 150A
- Jennifer Peterson, Director, Site Start Up and Regulatory
"Centralized Ethics: How a Unique Partnership between a CRO and an IRB is Changing the Regulatory and Ethics Review"
Session, Tuesday, June 16, 8 - 9 a.m., Room 150A
- Hiren R. Mehta, Research Scientist, Clinical Pharmacology
"Enhancing Pharmacokinetic Studies to Support Tier 2 Labeling Claims for Abuse Deterrent Opioids"
Poster Presentation, Wednesday, June 17, 9:49 – 9:54 a.m., Exhibit Hall Entrance A
- Daniel Mazzolenis, Senior Medical Director, Global Oncology Hematology
"Hemophilia as a Showcase of Rare/Orphan Diseases: Do Regulatory Paradigms need Updating?"
Symposium, Wednesday, June 17, 10:30 a.m. - 12 p.m., Room 145B
- Jill Collins, Senior Director, Clinical Innovation
"Risk-Based Monitoring: Case Studies of Successful Implementation"
Session, Wednesday, June 17, 3:30 - 5 p.m., Room 145A
- Dave Burnham, Vice President, Strategic Alliances
"Strategic Partnership Case Study"
Symposium, Thursday, June 18, 9 - 10:30 a.m., Room 150A
Connect with us
About INC Research
INC Research (Nasdaq:INCR) is a leading global contract research organization (CRO) providing the full range of Phase I to Phase IV clinical development services for the biopharmaceutical and medical device industry. Leveraging the breadth of our service offerings and the depth of our therapeutic expertise across multiple patient populations, INC Research connects customers, clinical research sites and patients to accelerate the delivery of new medicines to market. The Company was ranked "Top CRO to Work With" among large global CROs in the 2015 CenterWatch Global Investigative Site Relationship Survey. INC Research is headquartered in Raleigh, N.C., with operations across six continents and experience spanning more than 100 countries. For more information, please visit www.incresearch.com.
CONTACT: Investors: Ronnie Speight, +1 919 745 2745 Media: Lee Kennedy, +1 919 666 0772Source:INC Research